New stock news | Real Biotech files for Hong Kong Stock Exchange for the third time

According to the disclosure of the Hong Kong Stock Exchange on November 9th, ZhenShiBioTech Co., Ltd. (hereinafter referred to as ZhenShiBio) has submitted an application to the Hong Kong Stock Exchange main board, with CICC as its exclusive sponsor. This is the company's third time applying for listing on the Hong Kong Stock Exchange, having previously submitted applications on August 4, 2022, and February 18, 2025. ZhenShiBio is a biotechnology company founded in 2012 with a focus on innovative research and development, specializing in the development, manufacturing, and commercialization of innovative drugs for viral infections, tumors, and cardiovascular and cerebrovascular diseases. The company has developed a comprehensive drug portfolio, mainly including five candidate drugs: (i) the core product Azvudine, a drug conditionally approved in China for the treatment of HIV infection and COVID-19, with the company developing monotherapy (for the treatment of multiple myeloma, lymphoma, and acute leukemia) as well as four combination therapies, including Azvudine/PD-1 (for the treatment of liver cancer and colorectal cancer), Azvudine/Doritinib (for the treatment of non-small cell lung cancer), Azvudine/CL-197 (for the treatment of HIV), and Azvudine/CTX (for the treatment of lymphoma); (ii) the core product CL-197 for long-term treatment of HIV infection; (iii) the core product Doritinib for the treatment of non-small cell lung cancer; (iv) ZSSW-136 for the treatment of malignant tumors; and (v) MTB-1806 for the treatment of acute ischemic stroke.